TY - JOUR A2 - Bensoussan, Alan AU - Wang, Jie AU - Yang, Xiaochen AU - Chu, Fuyong AU - Chen, Jianxin AU - He, Qingyong AU - Yao, Kuiwu AU - Teng, Fei AU - Gao, Yonghong AU - Xing, Yanhui AU - Wu, Aiming AU - Xing, Yanwei PY - 2013 DA - 2013/05/08 TI - The Effects of Xuefu Zhuyu and Shengmai on the Evolution of Syndromes and Inflammatory Markers in Patients with Unstable Angina Pectoris after Percutaneous Coronary Intervention: A Randomised Controlled Clinical Trial SP - 896467 VL - 2013 AB - We evaluated the effects of the Xuefu Zhuyu capsule (XFZY) and the Shengmai capsule (SM) on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris (UAP) after percutaneous coronary intervention (PCI).90名UAP病人随机平均分配三大类:XFZY组、SM组和abo组,每个组有30名病人六大综合因子(包括Qi缺漏、yin缺缺缺、Yang缺缺缺、Belegm和Qi悬浮)和四大煽动性标志(高敏C-反应蛋白(Hs-CRP)、Entelins-1(ET-1)、矩阵金属蛋白-9(MMP-9)和Agysteine(Hcy))总论说,UAP患者自PCI跟踪这些趋势后所呈现综合症的演化(1) 缺损综合症在12周内逐步增加,但超重综合症先逐步下降,继PCI后温和增加XFZY和SM可防止超重综合症在后期增加,防止缺缺综合症在所有阶段增加3) XFZY和SMCAN降低煽动标志水平,特别是在PCI后期阶段SN-1741-427XUR-https://doi.org/10.1155/2013/896467DO-10.1155/2013/896467JF-证据辅助替代药PB-Hindawi出版公司KW-ER-ER